Abstract
Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior, body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased in the GALP group compared with the vehicle group, whereas hepatic fatty acid β-oxidation-related gene mRNA levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an inhibitory effect on lipid accumulation in the liver.
Keywords: GALP, fatty liver, lipid metabolism, high fat diet, DIO, triglycerides.
Current Pharmaceutical Design
Title:Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity
Volume: 23 Issue: 25
Author(s): Satoshi Hirako, Nobuhiro Wada, Haruaki Kageyama, Fumiko Takenoya, Hyounju Kim, Yuzuru Iizuka, Akiyo Matsumoto, Mai Okabe and Seiji Shioda*
Affiliation:
- Hoshi University School of Pharmacy and Pharmaceutical Sciences Global Research Center for Innovative Life Science, Peptide Drug Innovation, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501,Japan
Keywords: GALP, fatty liver, lipid metabolism, high fat diet, DIO, triglycerides.
Abstract: Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior, body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased in the GALP group compared with the vehicle group, whereas hepatic fatty acid β-oxidation-related gene mRNA levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an inhibitory effect on lipid accumulation in the liver.
Export Options
About this article
Cite this article as:
Hirako Satoshi , Wada Nobuhiro , Kageyama Haruaki, Takenoya Fumiko , Kim Hyounju, Iizuka Yuzuru , Matsumoto Akiyo , Okabe Mai and Shioda Seiji*, Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity, Current Pharmaceutical Design 2017; 23 (25) . https://dx.doi.org/10.2174/1381612823666170321095950
DOI https://dx.doi.org/10.2174/1381612823666170321095950 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research Licofelone-A Novel Analgesic and Anti-Inflammatory Agent
Current Topics in Medicinal Chemistry Vitamin D Supplementation in Diabetic Foot Ulcers: A Current Perspective
Current Diabetes Reviews Looming of Ecological Toxinology
Venoms and Toxins The Impact of Body Mass Index and Type 2 Diabetes on Breast Cancer: Current Therapeutic Measures of Prevention
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Safety Analysis of Bapineuzumab in the Treatment of Mild to Moderate Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Combinatorial Chemistry & High Throughput Screening Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Current Pharmaceutical Design About Mechanism of Gas Transport Function and Side Reactions of Perfluorocarbon Nano-dispersions
Current Bionanotechnology (Discontinued) Myoglobin as a New Fluorescence Probe to Sense H2S
Protein & Peptide Letters The Relevance of New Drug Combinations for Modern Tuberculosis Treatment - A Patent Perspective
Recent Patents on Anti-Infective Drug Discovery Clinical Perspectives on the Role of Anti-Platelet and Statin Therapy in Patients with Vascular Diseases
Current Vascular Pharmacology Investigation of Cytotoxic Effects of Oxymetazoline on Lungs in a Rat Model of Rhinitis Medicamentosa
Current Molecular Pharmacology Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke
Current Pharmaceutical Design Depression in Coronary Heart Disease Patients: Etiological and Screening Issues
Current Psychiatry Reviews Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)
Current Drug Targets Mechanisms of Endogenous Endothelial Repair in Stroke
Current Pharmaceutical Design The Implication of Behavioral and Molecular Factors on COVID-19 Infection
New Emirates Medical Journal